Pyxis Oncology, Inc. reported its financial results for the second quarter ended June 30, 2025. The company also provided an update on its clinical programs, noting that the Phase 1 monotherapy expansion study of micvotabart pelidotin (MICVO) for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients is progressing well, with preliminary data expected in the second half of 2025 and first half of 2026.
The Phase 1/2 combination study of MICVO and KEYTRUDA® (pembrolizumab) is also progressing well, with preliminary data anticipated in the second half of 2025. These updates indicate continued advancement of the company's lead therapeutic candidate.
Additionally, Pyxis Oncology received a $2.8 million, net of tax, milestone payment from Simcere Pharmaceutical Group Limited. This payment was for the approval of suvemcitug (BD0801) in China by the National Medical Products Administration. The company reiterated its expected cash runway through data milestones and into the second half of 2026.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.